effort
toward
develop
vaccin
middl
east
respiratori
syndrom
coronaviru
merscov
yield
promis
result
util
varieti
platform
sever
vaccin
approach
shown
efficaci
anim
model
begun
enter
clinic
trial
review
summar
current
progress
toward
merscov
vaccin
highlight
potenti
roadblock
identifi
previou
attempt
gener
coronaviru
vaccin
virus
preclin
vaccin
develop
sarscov
merscov
larg
aim
stimul
robust
immun
respons
viral
envelopeprotrud
spike
glycoprotein
class
fusion
protein
andor
nucleocapsid
n
protein
merscov
proteolyt
cleav
host
furin
matur
domain
respons
bind
well
domain
contain
two
heptadrepeat
region
facilit
membran
fusion
figur
domain
divid
ntermin
domain
ntd
associ
bind
sialic
acid
receptor
bind
domain
rbd
compris
major
ctermin
domain
cryoelectron
microscopi
studi
shown
rbd
flexibl
open
upward
away
viral
envelop
order
establish
contact
may
expos
second
proteas
cleavag
site
within
cleavag
necessari
membran
fusion
upon
viral
entri
central
viral
entri
help
explain
antibodi
target
potent
neutral
hand
cov
n
protein
abundantli
express
infect
immun
sarscov
n
induc
strongli
neutral
antibodi
like
n
display
viral
surfac
howev
n
conserv
within
cov
lineag
vaccin
sarscov
n
shown
induc
cytotox
cell
respons
mice
therefor
n
may
help
induc
cellmedi
immun
cov
infect
may
cell
respons
recov
merscov
patient
particularli
strong
toward
n
peptid
howev
vaccin
nbase
immunogen
may
carri
risk
associ
h
eosinophil
immun
enhanc
may
sbase
vaccin
notwithstand
protect
afford
robust
immun
respons
gener
target
vaccin
candid
merscov
review
summar
current
state
merscov
vaccin
candid
also
describ
potenti
barrier
merscov
vaccin
efficaci
first
surfac
research
develop
sarscov
vaccin
recent
year
viral
zoonot
diseas
caus
outbreak
mark
rapid
spread
high
mortal
includ
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
swine
flu
pandem
ebola
outbreak
west
africa
outbreak
difficult
predict
new
strain
emerg
reemerg
zoonot
reservoir
coronavirus
cov
larg
positivestrand
rna
virus
order
nidoviral
consid
minor
human
pathogen
caus
coldlik
symptom
occasion
associ
pneumonia
sever
diseas
howev
emerg
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
member
lineag
b
c
respect
mark
shift
understand
pathogen
potenti
coronavirus
virul
virus
genet
similar
current
circul
bat
cov
may
pose
threat
futur
zoonos
sinc
emerg
merscov
saudi
arabia
confirm
case
report
least
countri
overal
mortal
rate
http
wwwwhointemergenciesmerscov
addit
sever
diseas
note
age
immunocompromis
chronic
health
condit
camel
show
seroposit
merscov
archiv
sera
date
back
serv
intermedi
host
abl
spread
viru
human
may
spread
infect
persontoperson
rang
therapeut
explor
cov
diseas
merscov
vaccin
remain
scalabl
costeffect
prophylact
measur
current
vaccin
merscov
avail
although
sever
candid
develop
use
varieti
approach
vaccin
studi
initi
hamper
lack
small
anim
model
merscov
diseas
rodent
possess
homologu
dipeptidyl
peptidas
human
receptor
merscov
rodent
homologu
incompat
merscov
infect
howev
sever
vivo
approach
develop
overcom
barrier
facilit
merscov
vaccin
test
small
anim
model
preclin
vaccin
develop
sarscov
merscov
larg
aim
stimul
robust
immun
respons
viral
envelopeprotrud
spike
glycoprotein
class
fusion
protein
andor
nucleocapsid
n
protein
merscov
proteolyt
cleav
host
furin
matur
domain
respons
bind
well
domain
contain
two
heptadrepeat
region
facilit
membran
fusion
figur
domain
divid
ntermin
domain
ntd
associ
bind
sialic
acid
receptor
bind
domain
rbd
compris
major
ctermin
domain
cryoelectron
microscopi
studi
shown
rbd
flexibl
open
upward
away
viral
envelop
order
establish
contact
may
expos
second
proteas
cleavag
site
within
cleavag
necessari
membran
fusion
upon
viral
entri
central
viral
entri
help
explain
antibodi
target
potent
neutral
hand
cov
n
protein
abundantli
express
infect
immun
sarscov
n
induc
strongli
neutral
antibodi
like
n
display
viral
surfac
howev
n
conserv
within
cov
lineag
vaccin
sarscov
n
shown
induc
cytotox
cell
respons
mice
therefor
n
may
help
induc
cellmedi
immun
cov
infect
may
cell
respons
recov
merscov
patient
particularli
strong
toward
n
peptid
howev
vaccin
nbase
immunogen
may
carri
risk
associ
eosinophil
immun
enhanc
may
sbase
vaccin
notwithstand
protect
afford
robust
immun
respons
gener
target
vaccin
candid
merscov
review
summar
current
state
merscov
vaccin
candid
also
describ
potenti
barrier
merscov
vaccin
efficaci
first
surfac
research
develop
sarscov
vaccin
merscov
spike
glycoprotein
class
fusion
protein
target
major
vaccin
candid
exist
natur
trimer
form
shown
simplifi
diagram
dipeptidyl
peptidas
receptor
domain
domain
rbd
receptor
bind
domain
ntd
ntermin
domain
tmd
transmembran
domain
structur
configur
adapt
subunit
vaccin
compris
one
immunogen
compon
deriv
pathogen
gain
popular
recent
decad
due
rel
eas
product
reduc
risk
vivo
compar
vaccin
type
involv
live
viru
name
live
attenu
vaccin
viral
vector
vaccin
even
improperli
prepar
inactiv
vaccin
known
studi
recov
sarscov
patient
antibodi
gener
receptor
bind
domain
rbd
longlast
year
neutral
rbd
merscov
glycoprotein
initi
map
region
span
residu
antisera
rbd
proteinimmun
mice
rabbit
protect
vitro
infect
merscov
studi
explor
immun
correl
protect
intranas
administr
rbd
protein
induc
immunoglobulin
ig
lung
iga
neutral
antibodi
nab
untyp
antibodi
shown
function
inhibit
free
viru
infect
cell
well
cellmedi
respons
measur
product
antigenstimul
splenocyt
subsequ
studi
rbd
protein
fuse
fragment
crystalliz
fc
region
human
increas
vivo
halflif
immunogen
profil
immunogen
region
rbd
indic
residu
bound
highest
affin
solubl
induc
highest
nab
titer
administ
mice
rabbit
rangerefin
rbd
protein
vaccin
stabli
express
modifi
highyield
cho
cell
line
purifi
adjuv
addavax
tm
rbd
protein
vaccin
protect
administ
intramuscularli
transgen
mice
express
human
evid
immunolog
toxic
eosinophil
immun
enhanc
sinc
glycoprotein
exist
trimer
form
virion
qualiti
lost
shorten
form
protein
trimer
rbd
protein
vaccin
gener
contain
foldon
trimer
motif
rbd
protein
trimer
shown
elicit
longlast
nab
protect
challeng
mice
independ
monomer
rbd
protein
vaccin
develop
test
rhesu
macaqu
reduc
mersassoci
lung
patholog
reduc
viral
load
adjuv
alum
administ
intramuscularli
threedos
regimen
prior
challeng
final
rbd
protein
encod
sequenc
differ
strain
merscov
shown
induc
crossneutr
antibodi
diverg
human
camel
merscov
strain
well
monoclon
antibodi
mab
escap
mutant
confirm
promis
rbd
valid
vaccin
target
target
entir
glycoprotein
advantag
includ
nonrbd
neutral
epitop
includ
conserv
domain
protein
nanoparticl
protein
aggreg
contain
fulllength
propos
subunit
vaccin
nanoparticl
vaccin
adjuv
tm
elicit
nab
mice
protect
adenovir
mice
merscov
challeng
measur
viral
titer
viral
rna
near
limit
detect
vaccin
mice
howev
despit
promis
result
antibodydepend
enhanc
ade
infect
previous
note
context
vaccin
fulllength
sarscov
protein
vaccin
ade
demonstr
full
length
merscov
studi
must
consid
potenti
issu
variat
fulllength
glycoprotein
vaccin
trimer
ectodomain
transmembran
domain
conform
lock
prefus
state
substitut
two
prolin
residu
domain
work
relat
fusion
protein
f
glycoprotein
respiratori
syncyti
viru
shown
stabil
glycoprotein
prefus
state
help
elicit
stronger
neutral
antibodi
respons
prefus
administ
mice
elicit
sera
greater
neutral
activ
panel
pseudovirus
bear
strainspecif
variant
merscov
compar
wildtyp
sinc
domain
cov
conserv
domain
target
epitop
may
provid
broader
protect
differ
merscov
strain
lineag
c
rbdand
fulllength
sbase
protein
vaccin
build
upon
prior
vaccin
effort
sarscov
contrast
vaccin
target
ntermin
domain
ntd
offer
novel
target
ntd
contain
rbd
merscov
howev
ntd
bind
sialic
acid
key
infect
certain
cell
type
immun
ntd
protein
protect
merscov
challeng
adenovir
mice
induc
cellmedi
respons
splenocyt
product
product
product
well
humor
respons
igg
nab
although
nab
titer
lower
compar
rbd
protein
vaccin
overal
result
suggest
target
domain
outsid
rbd
may
viabl
strategi
merscov
vaccin
dna
vaccin
offer
rapid
platform
design
deliv
immunogen
protein
typic
encod
plasmid
vector
inject
tissu
accompani
electropor
dna
vaccin
administr
via
electropor
test
clinic
trial
immunogen
compar
vaccin
type
predominantli
lowgrad
advers
event
report
vivo
express
plasmidencod
protein
recapitul
nativ
posttransl
modif
maintain
capac
stimul
humor
cellmedi
immun
concern
safeti
dna
vaccin
potenti
integr
host
cell
chromosom
voic
earli
develop
integr
use
variou
plasmid
insert
appear
extrem
rare
sever
dna
vaccin
merscov
report
date
tm
proprietari
optim
plasmid
vaccin
vector
develop
merscov
vaccin
encod
consensu
merscov
glycoprotein
contain
codon
proprietari
optim
well
ige
leader
sequenc
promot
express
mrna
export
intramuscular
administr
construct
electropor
induc
antibodi
crossmerscovstrain
neutral
antigenspecif
polyfunct
cell
respons
rhesu
macaqu
humor
cellmedi
immun
respons
correl
minim
lung
patholog
reduc
lung
viral
load
upon
merscov
challeng
studi
report
nab
induct
dromedari
camel
indic
vaccin
could
use
zoonot
reservoir
build
upon
preclin
result
tm
vaccin
complet
phase
clinic
trial
second
vaccin
platform
util
plasmid
vector
engin
high
transgen
express
enhanc
cellmedi
respons
vaccin
regimen
consist
intramuscular
administr
merscov
strain
fulllength
encod
electropor
alpo
adjuv
protein
booster
induc
nab
rhesu
macaqu
week
follow
booster
vaccin
result
lower
lung
patholog
upon
challeng
merscov
strain
studi
fulllength
protein
vaccin
induc
higher
nab
titer
mice
primeboost
combin
involv
construct
encod
either
transmembran
domain
tmd
delet
consist
find
studi
report
mab
induc
domain
outsid
rbd
abl
neutral
merscov
pseudoviru
togeth
result
reiter
immunogen
potenti
nonrbd
epitop
includ
deriv
quaternari
trimer
structur
could
help
gener
immun
respons
abl
minim
escap
variant
deriv
immun
target
either
rbd
domain
alon
domain
merscov
strain
encod
pcdna
tm
proprietari
plasmid
tm
deriv
also
test
vaccin
platform
vaccin
induc
nab
mice
given
intramuscularli
antigenspecif
cytokin
product
includ
product
murin
splenocyt
addit
vaccin
protect
adenovir
mice
challeng
merscov
strain
moreov
vaccin
elicit
nab
fulllength
vector
result
attribut
increas
secret
protein
lack
tmd
greater
uptak
antigenpres
cell
separ
group
studi
compar
fulllength
sand
pcdna
tm
vaccin
found
vaccin
elicit
balanc
ratio
mice
compar
elicit
fulllength
suggest
balanc
h
h
respons
togeth
result
show
multipl
plasmid
vaccin
vector
encod
either
fulllength
domain
induc
adapt
immun
protect
merscov
challeng
viral
vector
vaccin
contain
one
immunogen
protein
pathogen
interest
context
attenu
viru
backbon
approach
take
advantag
cellular
entri
viru
well
adjuvant
viral
compon
induc
humor
strong
cellmedi
respons
earli
studi
viral
vector
vaccin
merscov
built
upon
establish
platform
subsequ
transit
newer
viral
vector
approach
venezuelan
equin
enceph
vee
viru
replicon
particl
vrp
alphavirusbas
platform
replac
vee
structur
gene
foreign
transgen
shown
induc
strong
humor
cellular
immun
respons
vrp
encod
merscov
elicit
nab
young
age
mice
addit
studi
vector
shown
immun
n
proteinexpress
vrp
protect
adenovir
mice
merscov
challeng
celland
manner
moreov
specif
n
protein
epitop
stimulatori
mice
transgen
human
leukocyt
antigen
highlight
relev
epitop
human
antigen
recognit
promot
cellmedi
immun
human
modifi
vaccinia
viru
ankara
mva
wellestablish
vaccin
platform
develop
encod
fulllength
merscov
vaccin
induc
nab
cell
respons
mice
also
protect
merscovinduc
histopatholog
adenovir
mice
challeng
moreov
minim
inflamm
lymph
node
hyperplasia
observ
site
inject
mvamerscov
vaccin
inject
intramuscularli
dromedari
camel
shown
induc
nab
limit
excret
infecti
viru
upon
intranas
challeng
merscov
phase
clinic
trial
underway
adenovirus
compos
third
platform
viral
vector
merscov
vaccin
adenovirusvector
vaccin
test
clinic
trial
wide
varieti
diseas
notabl
hiv
howev
efficaci
may
hamper
preexist
immun
preval
adenoviru
serotyp
exampl
preexist
immun
human
adenoviru
serotyp
shown
result
reduc
cell
respons
transgen
take
advantag
share
respiratori
rout
infect
merscov
adenoviru
fulllength
vaccin
develop
elicit
antigenspecif
igg
nab
administ
intramuscularli
mice
subsequ
intranas
boost
importantli
studi
detect
immun
vector
dromedari
camel
intend
vaccin
popul
moreov
camel
peripher
blood
mononuclear
cell
camelderiv
fibroblast
cell
line
abl
infect
anoth
vaccin
separ
develop
human
adenoviru
type
merscov
vaccin
adenoviru
type
enter
pathogen
potenti
use
oral
administ
vaccin
vaccin
report
induc
humor
respons
administ
intragastr
mice
addit
humor
respons
also
induc
longlast
cellmedi
respons
lung
spleen
administ
intramuscularli
one
final
merscov
immun
regimen
report
immun
follow
boost
nanoparticl
induc
sspecif
igg
nab
h
h
cellmedi
respons
mice
also
protect
adenovir
mice
merscov
challeng
circumv
seropreval
circul
human
adenovirus
chimpanze
adenovirus
also
develop
viral
vaccin
vector
enter
clinic
trial
merscov
sencod
vaccin
base
chimpanze
adenovir
vector
shown
induc
high
level
nab
cellmedi
respons
product
mice
week
postimmun
vaccin
construct
codonoptim
glycoprotein
sequenc
tissu
plasminogen
activ
tpa
gene
leader
sequenc
promot
secret
vaccin
protect
lethal
challeng
transgen
mous
model
base
previou
work
vector
demonstr
safeti
human
vaccin
undergo
phase
clinic
trial
sever
addit
viral
vector
employ
merscov
vaccin
measl
viru
vector
platform
develop
past
two
decad
fulllength
solubl
form
encod
measl
vaccin
strain
mv
induc
nab
prolifer
cell
sspecif
product
cytotox
activ
vaccin
also
protect
merscov
challeng
adenovir
mice
transgen
measl
viru
receptor
character
cell
respons
induc
vaccin
perform
note
higher
number
reactiv
cell
induc
vaccin
mv
induc
n
protein
use
vector
addit
antigenspecif
product
cell
could
induc
older
mice
month
old
level
near
induc
younger
mice
week
old
newcastl
diseas
viru
ndv
explor
vaccin
vector
infect
respiratori
tract
induc
system
mucos
immun
nonhuman
primat
nvd
vector
express
merscov
shown
induc
longlast
week
postimmun
nab
titer
camel
research
group
behind
studi
also
examin
vesicular
stomat
viru
vsv
viral
vector
express
vsv
revers
genet
system
shown
incorpor
onto
surfac
virion
rescu
cell
cultur
purifi
vaccin
abl
infect
cell
manner
induc
sspecif
igg
nab
mice
stimul
humor
cellmedi
respons
rhesu
macaqu
similar
vsv
platform
rabi
viru
rabv
vector
explor
inspir
studi
combin
rabi
ebola
vaccin
platform
dual
rabiesm
vaccin
propos
incorpor
merscov
domain
fuse
rabi
viru
g
protein
rabv
virion
vaccin
elicit
sspecif
igg
nab
fulli
protect
adenovir
mice
merscov
challeng
vsv
rabv
approach
describ
uniqu
encod
vector
genom
also
display
virion
surfac
final
viruslik
particl
vlp
compris
selfassembl
immunogen
protein
genom
also
use
viral
vector
baculoviru
vlp
contain
well
merscov
envelop
matrix
protein
elicit
rbdspecif
igg
respons
rhesu
macaqu
subsequ
baculoviru
vlp
vaccin
develop
focus
fusion
rbd
immunogen
protein
canin
parvoviru
vaccin
induc
rbdspecif
igg
nab
cellmedi
respons
includ
product
mice
also
activ
dendrit
cell
inguin
lymph
node
summari
varieti
viral
vector
vaccin
merscov
induc
promis
immun
respons
anim
model
often
demonstr
protect
challeng
final
approach
develop
merscov
vaccin
deliv
whole
viru
either
inactiv
live
attenu
vaccin
type
resembl
origin
viru
preserv
structur
featur
full
nearlyful
repertoir
immunogen
compon
inactiv
virus
may
contain
structur
deform
introduc
inactiv
unlik
attenu
virus
pose
risk
properli
inactiv
either
revers
virul
state
persist
infect
immunocompromis
patient
fewer
exampl
whole
viru
vaccin
compar
vaccin
type
develop
merscov
develop
inactiv
vaccin
merscov
stymi
prior
concern
sarscov
inactiv
vaccin
eosinophilrel
lung
patholog
observ
sarscov
vaccin
doubli
inactiv
formalin
uv
irradi
respons
particularli
notabl
age
mice
versu
young
mice
follow
heterolog
versu
homolog
challeng
similarli
immun
gammairradi
merscov
vaccin
adjuv
either
alum
elicit
nab
reduc
viral
titer
upon
challeng
mice
induc
eosinophilrel
lung
patholog
vaccin
mice
challeng
differ
inactiv
method
tri
second
merscov
inactiv
vaccin
formalininactiv
merscov
adjuv
alum
oligodeoxynucleotid
contain
unmethyl
cpg
motif
shown
elicit
level
nab
par
elicit
glycoproteinonli
vaccin
moreov
vaccin
offer
better
protect
alon
base
reduct
lung
viral
titer
adenovir
mice
merscov
challeng
remark
eosinophilmedi
vaccinerel
patholog
observ
anim
model
interestingli
also
shown
includ
tolllik
receptor
agonist
uvinactiv
sarscov
vaccin
reduc
h
patholog
lung
challeng
result
suggest
inactiv
cov
vaccin
may
remain
viabl
option
develop
right
inactiv
method
adjuv
live
attenu
vaccin
merscov
show
efficaci
anim
model
far
pursu
subsequ
studi
riskier
vaccin
type
live
attenu
vaccin
histor
offer
protect
varieti
threaten
ill
may
reserv
outbreak
scenario
offer
immunogen
robust
solut
cov
envelop
e
protein
import
virion
assembl
egress
also
shown
inhibit
host
cell
stress
respons
edelet
mutant
sarscov
previous
found
protect
vivo
sarscov
challeng
initi
studi
merscov
revers
genet
system
report
replicationcompet
propagationdefect
mutant
lack
e
protein
could
rescu
cell
cultur
e
express
tran
howev
edelet
mutant
rescu
lower
titer
compar
wildtyp
merscov
perhap
explain
mutant
develop
live
attenu
vaccin
candid
cov
compon
target
live
attenu
vaccin
develop
nonstructur
protein
contain
exoribonucleas
exon
essenti
replic
fidel
found
known
nidovirus
genom
size
greater
kb
stabl
defici
attenu
sarscov
young
age
immunocompromis
mice
abl
induc
protect
follow
vaccin
howev
exon
mutant
merscov
report
cov
gene
nonstructur
protein
omethyltransferas
involv
viral
mrna
cap
previous
inactiv
sarscov
live
attenu
vaccin
live
merscov
vaccin
similarli
attenu
type
interferonand
manner
immun
merscov
mutant
induc
nab
protect
crisprengin
mice
challeng
mouseadapt
merscov
strain
final
live
attenu
vaccin
lack
cov
accessori
protein
also
consid
cov
accessori
protein
dispens
viral
replic
shown
modul
interferon
signal
proinflammatori
cytokin
product
merscov
strain
lack
accessori
open
read
frame
orf
attenu
vivo
induc
nab
like
mutant
protect
crisprengin
mice
challeng
mouseadapt
merscov
strain
overal
whole
vaccin
approach
merscov
vaccin
appear
protect
safe
anim
model
aid
knowledg
gain
vaccin
develop
sarscov
contemporari
viral
diseas
merscov
vaccin
develop
effort
multipli
sinc
emerg
yield
promis
vaccin
candid
span
multipl
platform
tabl
nevertheless
key
barrier
vaccin
efficaci
first
note
sarscov
may
also
hold
true
merscov
sarscov
mortal
merscov
disproportion
affect
age
addit
immunocompromis
individu
chronic
condit
greater
risk
mortal
merscov
infect
univers
merscov
vaccin
must
offer
protect
vulner
class
peopl
studi
effect
propos
merscov
vaccin
model
immunosenesc
immunocompromis
chronic
condit
need
regard
vaccin
studi
sarscov
indic
vaccin
may
capabl
induc
protect
young
anim
fail
protect
age
anim
light
threat
relat
coronaviru
strain
emerg
merscov
vaccin
studi
must
also
consid
heterolog
challeng
model
ensur
safeti
vaccineinduc
immunopatholog
especi
older
individu
short
vaccineinduc
immunopatholog
especi
h
eosinophil
immun
enhanc
homolog
heterolog
challeng
specif
monitor
vulner
popul
interestingli
shown
patholog
result
merscov
challeng
lung
immunosuppress
rhesu
macaqu
lower
compar
nonimmunosuppress
macaqu
underscor
immunopathogen
compon
respiratori
diseas
caus
cov
differ
vaccin
platform
describ
herein
uniqu
advantag
disadvantag
sinc
sever
cov
diseas
maintain
immunopathogen
compon
success
vaccin
must
strike
balanc
protect
excess
immun
activ
seen
fulllength
well
inactiv
viru
vaccin
may
produc
immunopatholog
certain
condit
altern
protect
must
thorough
enough
prevent
nab
escap
phenomenon
invers
correl
number
immunogen
epitop
antibodi
induc
either
sarscov
merscov
poorli
crossneutr
across
respect
lineag
vaccin
contain
multipl
immunogen
epitop
would
perhap
also
offer
greater
crossprotect
heterolog
strain
within
lineag
emerg
especi
conserv
epitop
includ
vaccin
design
greater
understand
merscov
patholog
also
help
guid
futur
vaccin
develop
effort
illumin
possibl
critic
differ
vaccin
respons
merscov
sarscov
latter
larg
influenc
vaccin
develop
former
overal
merscov
vaccin
shown
encourag
result
preclin
studi
hope
vaccin
stand
safeti
consider
order
proceed
clinic
trial
develop
therapeut
treatment
critic
vaccin
carri
promis
mitig
futur
outbreak
allevi
diseas
burden
vulner
popul
includ
age
immunosuppress
healthcar
worker
famili
member
infect
patient
endem
area
author
declar
conflict
interest
